Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | HCN1 | O60741 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HCN4 | Q9Y3Q4 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14079927 | 1.00 | NPSR1 (0.37) | NPSR1OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL14079928 | 1.00 | NPSR1 (0.37) | NPSR1OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL14079926 | 0.97 | NPSR1 (0.34) | NPSR1OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL14079925 | 0.92 | NPSR1 (0.31) | NPSR1OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL91655 | 0.86 | CYP1A2 (0.32) | — | |
| SCHEMBL19293363 | 0.85 | — | — | |
| SCHEMBL1515302 | 0.83 | GRIN1 (0.37) | OPRM1OPRL1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL12774146 | 0.83 | GAA (0.32) | OPRM1OPRD1 | |
| SCHEMBL6496554 | 0.83 | GRIN1 (0.37) | OPRM1OPRL1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL633802 | 0.83 | GRIN1 (0.37) | OPRM1OPRL1OPRD1OPRK1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | NPSR1 4719/4885OPRM1 4583/4885OPRL1 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.